New CEO Ornskov Re-Organizes, Streamlines Shire’s Commercial And R&D Functions
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-line revenue was down slightly and Shire reduced its annual sales growth projections a bit too. But Shire’s first quarter earnings call centered on new CEO Flemming Ornskov’s decision to immediately implement a flatter management structure, reorganizing into five commercial business units and consolidating the R&D and business development operations.
You may also be interested in...
EMA Works On Defining Metadata From RWD Sources
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
UCB And Microsoft Expand AI Tie-Up Beyond COVID-19
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: